# Safety and Efficacy of PG101 for Dry Eye Syndrome

> **NCT02078661** · PHASE1,PHASE2 · COMPLETED · sponsor: **Rhodes Pharmaceuticals, L.P.** · enrollment: 72 (actual)

## Conditions studied

- Dry Eye Syndrome

## Interventions

- **DRUG:** PG101

## Key facts

- **NCT ID:** NCT02078661
- **Lead sponsor:** Rhodes Pharmaceuticals, L.P.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2014-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02078661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02078661, "Safety and Efficacy of PG101 for Dry Eye Syndrome". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02078661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*